Fresenius Medical Care announced today that its Global Medical Office has launched the My Reason campaign to promote patient enrolment in the company’s kidney-focused genomics registry, which was first introduced last year.
With the “ambitious goal” of enrolling more than 100,000 participants within five years, according to a company press release, the campaign will help build the registry into one of the largest of its kind by making participation a standard offering to patients in Fresenius Kidney Care dialysis centres in the USA.
The data collected by My Reason will serve as a critical research tool linking genomic and clinical data of chronic kidney disease (CKD) and end-stage kidney disease (ESKD) participants, with the intention of helping scientists better understand genetic variations in patients. Fresenius believes that, over time, this research will lead to more precise diagnoses and therapies that improve outcomes by individualising care.
“My Reason will help us build a ground-breaking registry of people with advanced kidney disease from diverse ethnic and cultural backgrounds,” said Franklin W Maddux, global chief medical officer of Fresenius Medical Care. “Pulled from such a large population of patients, when paired with existing clinical data, this data set at scale will help scientists untangle the complex interactions that lead to kidney injury and use genetic sequencing to better understand pathways of injury in kidney disease.”
Both patients and their family members residing in the USA are eligible to participate in the My Reason campaign that launched at the beginning of April, the release notes.
